Literature DB >> 8639863

Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool.

J G Gribben1, E C Guinan, V A Boussiotis, X Y Ke, L Linsley, C Sieff, G S Gray, G J Freeman, L M Nadler.   

Abstract

Graft-versus-host disease (GVHD) is initiated by adoptively transferred donor T cells that recognize host alloantigens. Whereas the absence of donor T-cell proliferation to host alloantigens in a mixed-leukocyte reaction does not predict freedom from GVHD, the frequency of alloreactive precursor helper T lymphocytes (pHTL) is predictive. Complete blockade of 87 family-mediated costimulation, but not of major histocompatibility complex recognition or adhesion, induces host alloantigenic-specific energy by reducing cytokine production below threshold levels necessary for common gamma chain signaling. The associated reduction of alloreactive pHTL frequency below that predictive for GVHD, without depletion of either nonallospecific T cells or hematopoietic progenitors, has led us to embark upon human clinical trials of haplomismatched allogeneic bone marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8639863

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

Review 1.  Management of graft-versus-host disease in paediatric bone marrow transplant recipients.

Authors:  M Zecca; F Locatelli
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

2.  CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors.

Authors:  Xupeng Ge; Julia Brown; Megan Sykes; Vassiliki A Boussiotis
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

3.  Expansion of allospecific regulatory T cells after anergized, mismatched bone marrow transplantation.

Authors:  Jeffrey K Davies; Lee M Nadler; Eva C Guinan
Journal:  Sci Transl Med       Date:  2009-10-07       Impact factor: 17.956

4.  Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.

Authors:  Jeff K Davies; Harjeet Singh; Helen Huls; Dongin Yuk; Dean A Lee; Partow Kebriaei; Richard E Champlin; Lee M Nadler; Eva C Guinan; Laurence J N Cooper
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

Review 5.  The role of B7 family molecules in hematologic malignancy.

Authors:  Paul Greaves; John G Gribben
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

6.  Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunity.

Authors:  Jeffrey K Davies; Dongin Yuk; Lee M Nadler; Eva C Guinan
Journal:  Transplantation       Date:  2008-09-27       Impact factor: 4.939

Review 7.  Transplantation of haploidentically mismatched stem cells for the treatment of malignant diseases.

Authors:  Franco Aversa; Massimo F Martelli
Journal:  Springer Semin Immunopathol       Date:  2004-09-11

8.  Ex vivo inhibition of NF-kappaB signaling in alloreactive T-cells prevents graft-versus-host disease.

Authors:  M J O'Shaughnessy; C Vogtenhuber; K Sun; R Sitcheran; A S Baldwin; W J Murphy; L Dang; B Jaffee; E Palmer; J S Serody; B R Blazar
Journal:  Am J Transplant       Date:  2009-03       Impact factor: 8.086

9.  Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies.

Authors:  Jeff K Davies; John G Gribben; Lisa L Brennan; Dongin Yuk; Lee M Nadler; Eva C Guinan
Journal:  Blood       Date:  2008-07-10       Impact factor: 22.113

Review 10.  Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation.

Authors:  George E Georges; Rainer Storb
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.